23 results about "Antacid" patented technology

The invention relates to a traditional Chinese medicine preparation for treating gastritis and a preparation method of the traditional Chinese medicine preparation. The traditional Chinese medicine preparation comprises the following raw materials in parts by weight: 40-50 parts of a traditional Chinese medicine composition, 10-15 parts of a sustained release agent, 25-32 parts of a filling agent and 3-8 parts of a flavoring agent, the slow release agent is modified carboxymethyl konjac glucomannan; the filling agent is cordyceps militaris polysaccharide and lactose; the flavoring agent is aspartame or sucralose. The sustained release agent is neohesperidin dihydrochalcone modified carboxymethyl konjac glucomannan, neohesperidin dihydrochalcone has the effect of inhibiting gastric acid secretion, and neohesperidin dihydrochalcone and the traditional Chinese medicine ingredient cuttlebone can synergistically play a role in preparing acid and jointly play a role in protecting gastric mucosa. Meanwhile, the cordyceps militaris polysaccharide has polysaccharide generality of thickening and stable film forming, and forms a compact network structure together with the modified carboxymethyl konjac glucomannan, and the obtained traditional Chinese medicine preparation has a good slow release effect.

A composition for the treatment of chronic pain and mixed pain sites may include a serotonin and norepinephrine reuptake inhibitor; a non-steroidal anti-inflammatory agent; optionally acetaminophen; optionally oxcarbamazepine; optionally an oral opioid antagonist; optionally an antacid; optionally an anti-epileptic; and optionally an opioid. A method for treating chronic pain and mixed pain sites may include administering, to a patient in need, a therapeutically effective dosage of the composition.

The invention discloses a composite preparation of a P-CABs drug and a combination of Vonoprazan fumarate and an antacid and a preparation method of the composite preparation. The formula of each unit of the preparation comprises 5-40 mg of a P-CABs drug, 400-1000 mg of sodium bicarbonate, 12 mg of a disintegrating agent and 8 mg of a lubricant. According to the compound preparation, the P-CABs medicine is combined with the antacid sodium bicarbonate, the gastric acid inhibiting effect can be rapidly, durably and mildly achieved, the disintegrating agent and the lubricating agent have the synergistic effect, the compound preparation has the advantages of being high in disintegration rate and dissolution rate when a good tabletting effect is formed, and the P-CABs medicine in the compound preparation is high in bioavailability and stability.

To provide an additive for a mushroom culture medium, the additive being capable of reducing a weighing error and improving the uniform mixing property of an antacid in a culture medium.SOLUTION: An additive for a mushroom culture medium of the present disclosure includes an extender and an antacid.SELECTED DRAWING: None

The invention provides an additive for a mushroom culture medium and a manufacturing method of the mushroom culture medium. The purpose of the present invention is to provide an additive for a mushroom culture medium, which can reduce the metering error and can improve the uniform mixing of an antacid in the culture medium. The additive for the mushroom culture medium comprises an incremental material and an anti-acid agent.

The invention discloses a rabeprazole pharmaceutical composition as well as a preparation method and application thereof. The invention provides a rabeprazole pharmaceutical composition, the rabeprazole pharmaceutical composition comprises an active pharmaceutical ingredient and an antacid, and the active pharmaceutical ingredient is selected from one or more of rabeprazole, rabeprazole sodium, other pharmaceutically acceptable salt forms, solvates and hydrates thereof. The rabeprazole pharmaceutical composition disclosed by the invention can inhibit the rabeprazole sodium from being damaged by gastric acid, and is small in side effect, rapid in treatment, relatively good in effect and high in patient compliance; the rabeprazole pharmaceutical composition has the advantages that the rabeprazole pharmaceutical composition is simple in preparation process and good in market prospect, and is an excellent medicine for treating peptic ulcer, and a pharmaceutical preparation can be delivered into the stomach by nasal feeding for some patients who cannot be administered by themselves, so that the effect of treating stomach diseases is achieved.

An aspect provides a pharmaceutical composite formulation containing: a first layer comprising a proton pump inhibitor or a pharmaceutically acceptable salt thereof as an active ingredient, a disintegrant, and a binder; and a second layer comprising, as an active ingredient, an antacid selected from magnesium hydroxide, magnesium oxide, or a mixture thereof.

A coated soft chew tablet includes a core in an amount of 60 to 99% by weight of the soft chew tablet. The core constituting a coherent uncooked mass includes one or more water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered monosaccharides and / or disaccharides in an amount of 10 to 45% by weight of the core, one or more texturizers in an amount of 0.1 to 15% by weight of the core, one or more active ingredients in an amount of 1 to 60% by weight of the core, and one or more solid sugar syrups in an amount up to 20% by weight of the core; and an outer coating surrounding the core in an amount of 1 to 40% by weight of the soft chew tablet.

A pharmaceutical composition of rabeprazole for treating peptic ulcers, a preparation method therefor and the use thereof. The composition contains a pharmaceutically active ingredient and an antacid, wherein the pharmaceutically active ingredient is selected from one or more of rabeprazole, rabeprazole sodium, and other pharmaceutically acceptable salt forms, solvates and hydrates of rabeprazole.

The invention relates to the field of medicines for treating oral inflammations, and provides a PANX1 / P2X7R antagonist and application thereof in preparation of a medicine for treating oral inflammations through a synergistic effect with red laser irradiation. Wherein the PANX1 / P2X7R antagonist comprises a sulfonated triphenylmethane dye, a gel material, an antacid, a humectant, a preservative, a solvent and other acceptable components. Wherein the first application is the application of the PANX1 / P2X7R antagonist in preparation of medicines for treating oral inflammation; the second application is the application of the PANX1 / P2X7R antagonist in preparation of a medicine for treating oral inflammation under the synergistic effect with red laser irradiation; the PANX1 / P2X7R antagonist is combined with red laser irradiation to serve as a regulator of ATP inside and outside cells, and remarkable synergistic anti-inflammatory, anti-oxidation, antibacterial and repair-promoting effects are shown.

The objective is to provide an additive for mushroom culture media that can reduce weighing errors and improve the uniform mixing of antacids in the culture media. [Solution] The mushroom culture medium additive of this disclosure comprises a bulking agent and an antacid.

This invention relates to coated soft chewable tablets, the soft chewable tablets comprising: a core, in an amount of 60% to 99% by weight of the soft chewable tablet, the core forming a cohesive, unheated mass and comprising: one or more water-soluble fibers, in an amount of 10% to 45% by weight of the core; one or more powdered monosaccharides and / or disaccharides, in an amount of 10% to 45% by weight of the core; one or more texture agents, in an amount of 0.1% to 15% by weight of the core; one or more active ingredients, in an amount of 1% to 60% by weight of the core; and one or more solid syrups, in an amount of up to 20% by weight of the core; and an outer coating surrounding the core, in an amount of 1% to 40% by weight of the soft chewable tablet.

The invention discloses a gastric acid resistant astaxanthin ester microcapsule and a preparation method thereof, and belongs to the technical field of astaxanthin ester processing and preparation. The preparation method comprises the following steps: dispersing starch octenyl succinate in water, gelatinizing, cooling, mixing with a chitosan solution, adding a sodium chloride solution, and freeze-drying to obtain rigid nanoparticles; dissolving natural astaxanthin ester in the oil phase to obtain astaxanthin ester oil; the preparation method comprises the following steps: dissolving rigid nanoparticles in water, adding astaxanthin ester oil, and shearing to obtain an astaxanthin ester emulsion; and mixing with a wall material solution, and carrying out spray drying to obtain the gastric acid-resistant astaxanthin ester microcapsule. The prepared astaxanthin ester microcapsule has gastric acid resistance stability, degradation of astaxanthin ester in the digestion and absorption process is reduced, more astaxanthin ester reaches the small intestine stage to be absorbed into the body, and the utilization efficiency of astaxanthin is improved. The preparation method is simple in preparation process, does not use a small molecular surfactant in the process, is green and safe, and can be efficiently applied to the field of functional foods.

This invention discloses a gelling material for treating gastric diseases and its preparation method, belonging to the field of pharmaceutical preparation technology. The gelling material is composed of 8-10g of Codonopsis pilosula extract, 6-10g of Bletilla striata extract, 6-8g of Dioscorea opposita extract, 2-4g of Citrus reticulata peel extract, 2-3g of gelatin, 2-4g of xylitol, 0.1-0.2g of citric acid, and 60.8-73.9g of purified water. As a carrier matrix, the gelling material of this invention exhibits good compatibility with commonly used antacids (such as calcium carbonate), PPIs (such as omeprazole), antibiotics (such as amoxicillin and clarithromycin), and traditional Chinese medicine extracts. During preparation, the above-mentioned active pharmaceutical ingredients (APIs) can be uniformly dispersed in the gel matrix, achieving integrated synergistic treatment of "mucosal protection + acid suppression / bactericidal action" without compromising their chemical stability or causing burst release problems, providing an ideal platform for developing compound gastric disease preparations.

An oral adhering lozenge including a sparsely water-soluble active ingredient is provided. In one aspect, an oral adhering lozenge having at least 5 milliequivalents (mEq) of acid neutralizing capacity is provided. The acid neutralization capacity may be achieved with at least 200 milligrams of a sparsely water-soluble antacid, such as calcium carbonate. To achieve a fast enough speed of dissolution with such a large quantity of sparsely water-soluble active ingredient, one or more water-soluble ingredients acting as a compression binder and / or bulking agent that dissolves quickly in water is included in an amount equal to greater than the sparsely soluble active ingredient in the non-adhesive layer.

The invention discloses a pantoprazole pharmaceutical composition as well as a preparation method and application thereof. The invention provides a pantoprazole pharmaceutical composition, which comprises an active pharmaceutical ingredient and an antacid, and the active pharmaceutical ingredient is selected from one or more of pantoprazole, pantoprazole sodium, other pharmaceutically acceptable salt forms, solvates and hydrates thereof; the antacid is selected from one or more of sodium bicarbonate, sodium carbonate, calcium carbonate, sodium hydroxide and magnesium hydroxide. The pantoprazole pharmaceutical composition can inhibit active ingredients from being damaged by gastric acid, and is good in prescription compatibility, stable in chemical property, fast in effect taking, good in curative effect, small in side effect, good in patient compliance, simple in preparation process and good in market prospect.

To provide a solid preparation in which temporal color tone change hard to occur when stored, despite that the preparation contains acetaminophen, ibuprofen or a salt thereof or their solvate, and one or more kinds of antacid selected from magnesium oxide and synthetic hydrotalcite.SOLUTION: A solid preparation contains the following components (a1), (a2), (a3) and (a4): (a1) acetaminophen; (a2) ibuprofen or a salt thereof or their solvate; (a3) one or more kinds of antacid selected from magnesium oxide and synthetic hydrotalcite; and (a4) one or more kinds of components selected from talc, light anhydrous silicic acid and mannitol.SELECTED DRAWING: None

A pantoprazole pharmaceutical composition, a preparation method therefor, and a use thereof. Provided is a pantoprazole pharmaceutical composition, comprising a pharmaceutically active component and an antacid, wherein: the pharmaceutically active component is selected from one or more of pantoprazole, pantoprazole sodium, other pharmaceutically acceptable salt forms of pantoprazole, and solvates and hydrates thereof; and the antacid is selected from one or more of sodium bicarbonate, sodium carbonate, calcium carbonate, sodium hydroxide, and magnesium hydroxide. The pantoprazole pharmaceutical composition can inhibit the active component from being destroyed by gastric acid, has good prescription compatibility, stable chemical properties, rapid effect, good efficacy, few side effects and good patient compliance, and has simple preparation process steps and good market prospects.

The present invention relates to a coated soft chew tablet, the soft chew tablet comprising: a core in an amount of 60 to 99% by weight of the soft chew tablet, the core constituting a coherent uncooked mass comprising: one or more water soluble fibers in an amount of 10 to 45% by weight of the core, one or more powdered monosaccharides and / or disaccharides in an amount of 10 to 45% by weight of the core, one or more texturizers in an amount of 0.1 to 15% by weight of the core, one or more active ingredients in an amount of 1 to 60% by weight of the core, and one or more solid sugar syrups in an amount up to 20% by weight of the core; and an outer coating surrounding the core in an amount of 1 to 40% by weight of the soft chew tablet.

The invention discloses an absorbable tissue strengthening material loaded with an antacid agent and a preparation method of the absorbable tissue strengthening material, and belongs to the technical field of biomedical materials. The invention is used for solving the problems of postoperative wound ulcer, difficulty in healing and the like caused by the side effect of taking aspirin or other NSAIDs for a long time after an ESD (Electro-Static Discharge) operation of a patient who suffers from an early gastric tumor and needs to be subjected to ESD treatment and anti-thrombus treatment at the same time in the prior art. The invention provides a preparation method of an absorbable tissue reinforcing material loaded with an anti-acid agent, which comprises the following steps: S1, mixing a polymer resin material and the anti-acid agent, and carrying out melt extrusion to form a composite melt trickle; cooling the composite melt trickles to form nascent filaments; s2, drafting and shaping the nascent filaments, and stripping and splitting the nascent filaments by adopting high-pressure water flow to prepare a polymer resin / antacid composite net; and cutting the polymer resin / antacid composite net to prepare the absorbable tissue reinforcing material loaded with the antacid.

An oral adhesive lozenge containing an active ingredient that is sparingly soluble in water is provided. In one embodiment, an oral adhesive lozenge having an acid neutralizing ability of at least 5 milliequivalents (mEq) is provided. The acid neutralizing ability can be achieved by using at least 200 mg of an antacid that is sparingly soluble in water, such as calcium carbonate. To achieve a sufficiently rapid dissolution rate of such a large amount of the water-spasmodic active ingredient, one or more water-soluble ingredients acting as a rapidly soluble compression binder and / or extender are included in a non-adhesive layer in an amount equal to or greater than that of the water-spasmodic active ingredient.

This invention relates to the treatment of chronic pain and mixed pain sites. Previously, treatment options for patients with chronic pain and mixed pain sites included switching to different pain medications and used of non-opioid alternatives. Embodiments of the present invention use a serotonin and norepinephrine reuptake inhibitor, a non-steroidal anti-inflammatory agent, optionally acetaminophen, optionally oxcarbamazepine, optionally an oral opioid antagonist, optionally an antacid, optionally an anti-epileptic, and optionally an opioid.

The present invention relates to a pharmaceutical combination preparation comprising ilaprazole, an antacid, and an alkalizing agent and, more specifically, to a pharmaceutical combination preparation and a method for preparing same, wherein decomposition of ilaprazole in the stomach is prevented without enteric coating to improve stability, thereby increasing bioavailability, and the quality and productivity of pharmaceutical products are improved due to uncomplicated manufacturing processes and excellent storage stability of the preparation.